Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

Abstract

Melanoma is the most aggressive form of skin cancer, characterized by a poor prognosis, and its incidence has risen rapidly over the past 30 years. Recent therapies, notably immunotherapy and targeted therapy, have significantly improved the outcome of patients with metastatic melanoma. Previously dismal five-year survival rates of below 5% have shifted to over 50% of patients surviving the five-year mark, marking a significant shift in the landscape of melanoma treatment and survival. Unfortunately, about 50% of patients either do not respond to therapy or experience early or late relapses following an initial response. The underlying mechanisms for primary and secondary resistance to targeted therapies or immunotherapy and relapse patterns remain not fully identified. However, several molecular pathways and genetic factors have been associated with melanoma resistance to these treatments. Understanding these mechanisms paves the way for creating novel treatments that can address resistance and ultimately enhance patient outcomes in melanoma. This review explores the mechanisms behind immunotherapy and targeted therapy resistance in melanoma patients. Additionally, it describes the treatment strategies to overcome resistance, which have improved patients’ outcomes in clinical trials and practice.

Keywords

Immunotherapy / BRAF / resistance / melanoma / overcoming resistance

References

[1] Naik PP.Cutaneous malignant melanoma: a review of early diagnosis and management.World J Oncol2021;12:7-19 PMCID:PMC7935621

[2] Siegel RL,Jemal A.Cancer statistics, 2024.CA Cancer J Clin2024;74:12-49

[3] Thornton J,Singh CK,Shirley CA.Mechanisms of immunotherapy resistance in cutaneous melanoma: recognizing a shapeshifter.Front Oncol2022;12:880876 PMCID:PMC9066268

[4] Seth R,Messersmith H.Systemic therapy for melanoma: ASCO guideline update.J Clin Oncol2023;41:4794-820

[5] Hodi FS,McDermott DF.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med2010;363:711-23 PMCID:PMC3549297

[6] Liu FX,Diede SJ.Real-world experience with pembrolizumab in patients with advanced melanoma: a large retrospective observational study.Medicine2019;98:e16542 PMCID:PMC6709121

[7] Johnson DB,Sosman JA.Nivolumab in melanoma: latest evidence and clinical potential.Ther Adv Med Oncol2015;7:97-106 PMCID:PMC4346215

[8] Wolchok JD,Gonzalez R.Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma.J Clin Oncol2022;40:127-37 PMCID:PMC8718224

[9] Ascierto PA,Grob JJ.The role of BRAF V600 mutation in melanoma.J Transl Med2012;10:85 PMCID:PMC3391993

[10] Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16. PMCID:PMC3549296

[11] Lugowska I,Kozak K.Trametinib: a MEK inhibitor for management of metastatic melanoma.Onco Targets Ther2015;8:2251-9 PMCID:PMC4556032

[12] Long GV,Gogas H.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.N Engl J Med2014;371:1877-88

[13] Ismail RK,de Boer A.Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Melanoma Res2022;32:460-8 PMCID:PMC9612708

[14] Newell F,Johansson PA.Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance.Cancer Cell2022;40:88-102.e7

[15] Lipson EJ.Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.Clin Cancer Res2011;17:6958-62 PMCID:PMC3575079

[16] Buchbinder EI.CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition.Am J Clin Oncol2016;39:98-106 PMCID:PMC4892769

[17] Keir ME,Freeman GJ.PD-1 and its ligands in tolerance and immunity.Annu Rev Immunol2008;26:677-704 PMCID:PMC10637733

[18] Kwok G,Chiu JW,Kwong YL.Pembrolizumab (Keytruda).Hum Vaccin Immunother2016;12:2777-89 PMCID:PMC5137544

[19] Martin-Liberal J,Larkin J.Safety of pembrolizumab for the treatment of melanoma.Expert Opin Drug Saf2015;14:957-64

[20] Alsaab HO,Alzhrani R.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome.Front Pharmacol2017;8:561 PMCID:PMC5572324

[21] Kamada T,Tay C.PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.Proc Natl Acad Sci U S A2019;116:9999-10008 PMCID:PMC6525547

[22] Weber JS,Yu B.Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.J Clin Oncol2013;31:4311-8 PMCID:PMC3837092

[23] Geels SN,Sousa RS.Interruption of the intratumor CD8⁺ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy.Cancer Cell2024;42:1051-66.e7 PMCID:PMC11285091

[24] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017;168:707-23 PMCID:PMC5391692

[25] Robert C,Bondarenko I.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.N Engl J Med2011;364:2517-26

[26] Gide TN,Scolyer RA.Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma.Clin Cancer Res2018;24:1260-70

[27] Vukadin S,Kizivat T,Smolic M.Molecular mechanisms of resistance to immune checkpoint inhibitors in melanoma treatment: an update.Biomedicines2021;9:835 PMCID:PMC8301472

[28] Parsa AT,Panner A.Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.Nat Med2007;13:84-8

[29] Xu C,Koyama S.Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.Cancer Cell2014;25:590-604 PMCID:PMC4112370

[30] Peng W,Liu C.Loss of PTEN promotes resistance to T cell-mediated immunotherapy.Cancer Discov2016;6:202-16 PMCID:PMC4744499

[31] Aguissa-Touré AH.Genetic alterations of PTEN in human melanoma.Cell Mol Life Sci2012;69:1475-91 PMCID:PMC11114653

[32] Bucheit AD,Siroy A.Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.Clin Cancer Res2014;20:5527-36 PMCID:PMC4216767

[33] Marzec M,Goradia A.Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).Proc Natl Acad Sci U S A2008;105:20852-7 PMCID:PMC2634900

[34] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer2012;12:252-64 PMCID:PMC4856023

[35] van Houdt IS,Moesbergen LM.Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.Int J Cancer2008;123:609-15

[36] Azimi F,Rumcheva P.Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.J Clin Oncol2012;30:2678-83

[37] Garcia-Lora A,Garrido F.MHC class I antigens, immune surveillance, and tumor immune escape.J Cell Physiol2003;195:346-55

[38] Al-Batran SE,Atmaca A.Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.Cancer Res2005;65:3937-41

[39] Jäger E,Altmannsberger M.Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.Int J Cancer1997;71:142-7

[40] Donia M,Kjeldsen JW.Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4+ T- cells, which dampen CD8+ T-cell antitumor reactivity.Cancer Res2015;75:3747-59

[41] Ladányi A,Somlai B.Density of DC-LAMP⁺ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor.Cancer Immunol Immunother2007;56:1459-69 PMCID:PMC11030123

[42] Ni K.The role of dendritic cells in T cell activation.Immunol Cell Biol1997;75:223-30

[43] Gerlini G,Dudli C,Pimpinelli N.Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.Am J Pathol2004;165:1853-63 PMCID:PMC1618726

[44] Koch F,Jennewein P.High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.J Exp Med1996;184:741-6 PMCID:PMC2192732

[45] Wu W,Wang Y.IL-37b suppresses T cell priming by modulating dendritic cell maturation and cytokine production via dampening ERK/NF-κB/S6K signalings.Acta Biochim Biophys Sin2015;47:597-603

[46] Gomez GVB,Monteiro LMO.Association of JAK/STAT genetic variants with cutaneous melanoma.Front Oncol2022;12:943483 PMCID:PMC9379289

[47] Shin DS,Escuin-Ordinas H.Primary resistance to PD-1 blockade mediated by JAK1/2 mutations.Cancer Discov2017;7:188-201 PMCID:PMC5296316

[48] Demunter A,Degreef H,van den Oord JJ.Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma.Virchows Arch2001;438:485-91

[49] Yang J,Liu B.Targeting VEGF/VEGFR to modulate antitumor immunity.Front Immunol2018;9:978 PMCID:PMC5943566

[50] Voron T,Marcheteau E.VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.J Exp Med2015;212:139-48 PMCID:PMC4322048

[51] Hodi FS,Soiffer RJ.Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.Proc Natl Acad Sci U S A2003;100:4712-7 PMCID:PMC153621

[52] Hodi FS,Lezcano C.Bevacizumab plus ipilimumab in patients with metastatic melanoma.Cancer Immunol Res2014;2:632-42 PMCID:PMC4306338

[53] Ott PA,Buchbinder EI.Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data.Front Oncol2015;5:202 PMCID:PMC4585112

[54] Uyttenhove C,Théate I.Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.Nat Med2003;9:1269-74

[55] Brody JR,Berger AC.Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.Cell Cycle2009;8:1930-4

[56] Holmgaard RB,Munn DH,Allison JP.Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.J Exp Med2013;210:1389-402 PMCID:PMC3698523

[57] Kjeldsen JW,Martinenaite E.A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.Nat Med2021;27:2212-23 PMCID:PMC8904254

[58] Li X,Burns C.Cooperative binding of Stat1-2 heterodimers and ISGF3 to tandem DNA elements.Biochimie1998;80:703-10

[59] Nicholas C.The Jak-STAT signal transduction pathway in melanoma. In: Tanaka Y, editor. Breakthroughs in melanoma research. InTech; 2011.

[60] Bald T,Lopez-Ramos D.Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.Cancer Discov2014;4:674-87

[61] Ribas A.Adaptive immune resistance: how cancer protects from immune attack.Cancer Discov2015;5:915-9 PMCID:PMC4560619

[62] Winder M.Mechanisms of drug resistance in melanoma. In: Mandalà M, Romano E, editors. Mechanisms of drug resistance in cancer therapy. Cham: Springer International Publishing; 2018. pp. 91-108.

[63] Zaretsky JM,Shin DS.Mutations associated with acquired resistance to PD-1 blockade in melanoma.N Engl J Med2016;375:819-29 PMCID:PMC5007206

[64] Wang H,Wei J.Beta2-microglobulin(B2M) in cancer immunotherapies: biological function, resistance and remedy.Cancer Lett2021;517:96-104

[65] Restifo NP,Kawakami Y,Yannelli JR.Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.J Natl Cancer Inst1996;88:100-8 PMCID:PMC2248456

[66] del Campo AB,Carretero J.Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.Int J Cancer2014;134:102-13

[67] Zhu C,Schubart A.The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.Nat Immunol2005;6:1245-52

[68] Kandel S,Li G.The TIM3/Gal9 signaling pathway: an emerging target for cancer immunotherapy.Cancer Lett2021;510:67-78 PMCID:PMC8168453

[69] Koyama S,Li YY.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Nat Commun2016;7:10501 PMCID:PMC4757784

[70] Taube JM,McMiller TL.Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade.Clin Cancer Res2015;21:3969-76 PMCID:PMC4558237

[71] Anderson AC,Kuchroo VK.Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation.Immunity2016;44:989-1004 PMCID:PMC4942846

[72] Finn L,Joseph RW.Therapy for metastatic melanoma: the past, present, and future.BMC Med2012;10:23 PMCID:PMC3308914

[73] Okuma T,Kambayashi Y,Aiba S.Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.J Dermatol2021;48:1419-22

[74] Twyman-Saint Victor C,Maity A.Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.Nature2015;520:373-7 PMCID:PMC4401634

[75] Woo SR,Goldberg MV.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.Cancer Res2012;72:917-27 PMCID:PMC3288154

[76] Legat A,Baumgaertner P.Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients - report of a Phase I/IIa clinical trial.Clin Cancer Res2016;22:1330-40

[77] Kreidieh FY.The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.Ther Adv Med Oncol2023;15:17588359231186027 PMCID:PMC10357068

[78] Su J,Cui Z.Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.Front Pharmacol2023;14:1349081 PMCID:PMC10806167

[79] Tawbi HA, Schadendorf D, Lipson EJ, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386:24-34. PMCID:PMC9844513

[80] Gide TN,Yaseen Z.Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.Oncoimmunology2023;12:2261248 PMCID:PMC10558007

[81] Aggarwal V,Vignali DAA.LAG-3 as the third checkpoint inhibitor.Nat Immunol2023;24:1415-22 PMCID:PMC11144386

[82] Falahat R,Putney RM.Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma.Proc Natl Acad Sci U S A2021;118:e2013598118 PMCID:PMC8053941

[83] Chipurupalli S,Dhanabal SP,Robinson N.Pharmacological STING activation is a potential alternative to overcome drug-resistance in melanoma.Front Oncol2020;10:758 PMCID:PMC7241280

[84] Xia T,Barber GN.Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis.Cancer Res2016;76:6747-59

[85] Nakamura T,Endo R.STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.J Immunother Cancer2021;9:e002852 PMCID:PMC8256839

[86] Sivan A,Hubert N.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science2015;350:1084-9 PMCID:PMC4873287

[87] Davar D,McCulloch JA.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.Science2021;371:595-602 PMCID:PMC8097968

[88] Schalper KA,Zhou M.Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.Nat Med2020;26:688-92 PMCID:PMC8127102

[89] Yeon M,Jung HS.Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma.Front Cell Dev Biol2020;8:486 PMCID:PMC7311641

[90] Weichert W.HDAC expression and clinical prognosis in human malignancies.Cancer Lett2009;280:168-76

[91] Hornig E,Graf SA,Berking C.Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.Exp Dermatol2016;25:831-8

[92] Woods DM,Villagra A,Sotomayor EM.HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade.Cancer Immunol Res2015;3:1375-85 PMCID:PMC4674300

[93] Soldozy S,Zheng DX.Oncolytic virotherapy for melanoma brain metastases, a potential new treatment paradigm?.Brain Sci2021;11:1260 PMCID:PMC8534242

[94] Garofalo M,Staniszewska M.Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model.Pharmaceutics2021;13:547 PMCID:PMC8070801

[95] Andtbacka RHI,Collichio F.Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.J Clin Oncol2015;33:2780-8

[96] Chesney JA,Long GV.Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma.J Clin Oncol2023;41:528-40 PMCID:PMC9870217

[97] Inozume T.Adoptive cell transfer therapy for melanoma.Exp Dermatol2023;32:250-5

[98] Rohaan MW,van den Berg JH.Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma.N Engl J Med2022;387:2113-25

[99] Ribas A.BRAF targeted therapy changes the treatment paradigm in melanoma.Nat Rev Clin Oncol2011;8:426-33

[100] Czarnecka AM,Fiedorowicz M.Targeted therapy in melanoma and mechanisms of resistance.Int J Mol Sci2020;21:4576 PMCID:PMC7369697

[101] Kortum RL.Path forward for RAF therapies: inhibition of monomers and dimers.Cancer Cell2015;28:279-81 PMCID:PMC7394233

[102] Kim A.The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Expert Opin Drug Discov2016;11:907-16 PMCID:PMC5443413

[103] Patel H,Mishra R.Current advances in the treatment of BRAF-mutant melanoma.Cancers2020;12:482 PMCID:PMC7072236

[104] Sullivan RJ.Resistance to BRAF-targeted therapy in melanoma.Eur J Cancer2013;49:1297-304

[105] Cohen JV.Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma.Clin Cancer Res2019;25:5735-42 PMCID:PMC6774830

[106] Dummer R,Gogas HJ.Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol2018;19:603-15

[107] Kozar I,Rothengatter S,Kreis S.Many ways to resistance: how melanoma cells evade targeted therapies.Biochim Biophys Acta Rev Cancer2019;1871:313-22

[108] Tangella LP,Gray ES.Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - a mini review.Biochim Biophys Acta Gen Subj2021;1865:129736

[109] Cui J,Zhang YQ.JNK pathway: diseases and therapeutic potential.Acta Pharmacol Sin2007;28:601-8

[110] Hammouda MB,Liu Y.The JNK signaling pathway in inflammatory skin disorders and cancer.Cells2020;9:857 PMCID:PMC7226813

[111] Riesenberg S,Siddaway R.MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.Nat Commun2015;6:8755 PMCID:PMC4659938

[112] Motti ML,Di Carluccio G,Carriero MV.MicroRNAs as key players in melanoma cell resistance to MAPK and immune checkpoint inhibitors.Int J Mol Sci2020;21:4544 PMCID:PMC7352536

[113] Fattore L,Pisanu ME.Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma.Cell Death Differ2019;26:1267-82 PMCID:PMC6748102

[114] Fateeva A,Chen S.Current state of melanoma therapy and next steps: battling therapeutic resistance.Cancers2024;16:1571 PMCID:PMC11049326

[115] Vergani E,Dugo M.Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.Oncotarget2016;7:4428-41 PMCID:PMC4826216

[116] Vergani E,Cossa M.miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.Cell Commun Signal2020;18:156 PMCID:PMC7510138

[117] Griffin M,Josephs DH.BRAF inhibitors: resistance and the promise of combination treatments for melanoma.Oncotarget2017;8:78174-92 PMCID:PMC5652848

[118] Johannessen CM,Kim SY.COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Nature2010;468:968-72 PMCID:PMC3058384

[119] Lim SY,Rizos H.Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.Cancer2017;123:2118-29

[120] Poulikakos PI,Janakiraman M.RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).Nature2011;480:387-90 PMCID:PMC3266695

[121] Shimizu Y,Suzuki M.Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.Cancer Lett2022;543:215799

[122] Sullivan RJ,Flaherty KT.A phase I study of LY3009120, a Pan-RAF inhibitor, in patients with advanced or metastatic cancer.Mol Cancer Ther2020;19:460-7

[123] Ottaviano M,Tortora M.BRAF gene and melanoma: back to the future.Int J Mol Sci2021;22:3474 PMCID:PMC8037827

[124] Fernandez MF,Sosman J.New approaches to targeted therapy in melanoma.Cancers2023;15:3224 PMCID:PMC10296143

[125] Swetter SM,Bichakjian CK.Guidelines of care for the management of primary cutaneous melanoma.J Am Acad Dermatol2019;80:208-50

[126] Germann UA,Markland W.Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (Ulixertinib).Mol Cancer Ther2017;16:2351-63

[127] Bédard PL,Kopetz S.First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.Cancer2018;124:315-24

[128] Subbiah V,Hess KR.Phase I study of the BRAF inhibitor vemurafenib in combination with the mammalian target of rapamycin inhibitor everolimus in patients with BRAF-mutated malignancies.JCO Precis Oncol2018;2:PO.18.00189 PMCID:PMC7446411

[129] Louveau B,Lesimple T.Phase I-II open label multicenter study of PD0332991 in BRAF^V600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.J Clin Oncol2019;37:9545

[130] Palamaris K,Gakiopoulou H.Histone deacetylase (HDAC) inhibitors: a promising weapon to tackle therapy resistance in melanoma.Int J Mol Sci2022;23:3660 PMCID:PMC8998190

[131] Eroglu Z,Gibney GT.Combined BRAF and HSP90 inhibition in patients with unresectable BRAF^V600E-mutant melanoma.Clin Cancer Res2018;24:5516-24 PMCID:PMC6195480

[132] Trisciuoglio D.New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy.Drug Discov Today2021;26:1126-35

[133] Vultur A,Krepler C.MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.Oncogene2014;33:1850-61 PMCID:PMC3769503

[134] Smith MP,Rowling EJ.Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy.Cancer Cell2016;29:270-84 PMCID:PMC4796027

[135] Boshuizen J,Krijgsman O.Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Nat Med2018;24:203-12

[136] Kichina JV,Kandel ES.PAK1 and therapy resistance in melanoma.Cells2023;12:2373 PMCID:PMC10572217

[137] King H,Wells CM.Role of p-21-activated kinases in cancer progression. Elsevier; 2014. pp. 347-87.

[138] Ho H,Kapadia R,White MA.RhoJ regulates melanoma chemoresistance by suppressing pathways that sense DNA damage.Cancer Res2012;72:5516-28 PMCID:PMC3548429

[139] Babagana M,Slabodkin H,Morrison C.P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.Mol Carcinog2017;56:1515-25 PMCID:PMC5392142

[140] Ong CC,Jakubiak D.P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.J Natl Cancer Inst2013;105:606-7

[141] Hu-Lieskovan S,Homet Moreno B.Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF^V600E melanoma.Sci Transl Med2015;7:279ra41 PMCID:PMC4765379

[142] Frederick DT,Cogdill AP.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Clin Cancer Res2013;19:1225-31 PMCID:PMC3752683

[143] Boni A,Dang P.Selective BRAF^V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.Cancer Res2010;70:5213-9

[144] Ribas A,Callahan M,Wolchok J.Hepatotoxicity with combination of vemurafenib and ipilimumab.N Engl J Med2013;368:1365-6

[145] Minor DR,Callahan MK,Hoos A.Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.Pigment Cell Melanoma Res2015;28:611-2 PMCID:PMC4744965

[146] Dummer R,Nathan P,Schadendorf D.Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review.JAMA Oncol2020;6:1957-66

[147] Sullivan RJ,Gonzalez R.Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.Nat Med2019;25:929-35

[148] Gutzmer R,Gogas H.Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF^V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2020;395:1835-44

[149] Ascierto PA,Fisher R.Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.Nat Med2019;25:941-6

[150] Ferrucci PF, Di Giacomo AM, Del Vecchio M, et al; KEYNOTE-022 international team. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer 2020;8:e001806. PMCID:PMC7768966

[151] Dummer R,Robert C.Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma.J Clin Oncol2022;40:1428-38 PMCID:PMC9061149